PRR highlights ---------------- * Progressing rapidly to commercialisation of world’s first ovarian cancer vaccine therapy treatment * Company has recently secured $12m equity funding facility, which funds commercialisation process * In final stages of US FDA IND process * Global ovarian cancer treatment market is massive; estimated to be worth US$3.6b in 2010 * Ovarian cancer has very high morbidity rate and currently there are no maintenance treatment products commercially available World class scientific advisory team * Will commence Pivotal Clinical Trial with US FDA mid-2009 at world leading Fred Hutchinson Cancer Centre in Seattle, USA, which has 3 Nobel Laureates on staff, then * Seek US FDA approval to license the product commercially and begin generating revenue for the Company * Have already commenced selected treatment of patients in Australia * Pursuing fast-track of commercialisation in other jurisdictions outside US FDA
